<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;fc=20230708114047&amp;ff=20231109031038&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;fc=20230708114047&amp;ff=20231109031038&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Thu, 09 Nov 2023 08:10:41 +0000</lastbuilddate>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Reply: C-Reactive Protein and Heart Failure in Patients With Established Cardiovascular Disease: Evidence From UK Biobank</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37940237/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109031038&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 14;82(20):e193. doi: 10.1016/j.jacc.2023.09.803.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37940237/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109031038&v=2.17.9.post6+86293ac">37940237</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.803>10.1016/j.jacc.2023.09.803</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37940237</guid>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Pascal M Burger</dc:creator>
<dc:creator>Frank L J Visseren</dc:creator>
<dc:creator>Jannick A N Dorresteijn</dc:creator>
<dc:date>2023-11-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: C-Reactive Protein and Heart Failure in Patients With Established Cardiovascular Disease: Evidence From UK Biobank</dc:title>
<dc:identifier>pmid:37940237</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.803</dc:identifier>
</item>
<item>
<title>C-Reactive Protein and Heart Failure in Patients With Established Cardiovascular Disease: Evidence From UK Biobank</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37940236/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109031038&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 14;82(20):e191-e192. doi: 10.1016/j.jacc.2023.08.052.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37940236/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109031038&v=2.17.9.post6+86293ac">37940236</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.052>10.1016/j.jacc.2023.08.052</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37940236</guid>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Jakub Morze</dc:creator>
<dc:creator>Andrzej Rynkiewicz</dc:creator>
<dc:date>2023-11-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>C-Reactive Protein and Heart Failure in Patients With Established Cardiovascular Disease: Evidence From UK Biobank</dc:title>
<dc:identifier>pmid:37940236</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.052</dc:identifier>
</item>
<item>
<title>Long-Term Incidence of Atrial Fibrillation in Patients With Autoimmune Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37940235/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109031038&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 14;82(20):1969-1971. doi: 10.1016/j.jacc.2023.09.802.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37940235/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109031038&v=2.17.9.post6+86293ac">37940235</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.802>10.1016/j.jacc.2023.09.802</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37940235</guid>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Guoli Sun</dc:creator>
<dc:creator>Ole Ahlehoff</dc:creator>
<dc:creator>Emil L Fosbøl</dc:creator>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Mikkel Faurschou</dc:creator>
<dc:creator>Jesper Hastrup Svendsen</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Jawad H Butt</dc:creator>
<dc:date>2023-11-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Long-Term Incidence of Atrial Fibrillation in Patients With Autoimmune Disease</dc:title>
<dc:identifier>pmid:37940235</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.802</dc:identifier>
</item>
<item>
<title>Member Engagement Key to Transforming Cardiovascular Care for All</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37940234/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109031038&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 14;82(20):1967-1968. doi: 10.1016/j.jacc.2023.09.820.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37940234/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109031038&v=2.17.9.post6+86293ac">37940234</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.820>10.1016/j.jacc.2023.09.820</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37940234</guid>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>B Hadley Wilson</dc:creator>
<dc:creator>Cathleen Biga</dc:creator>
<dc:creator>Joseph E Marine</dc:creator>
<dc:date>2023-11-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Member Engagement Key to Transforming Cardiovascular Care for All</dc:title>
<dc:identifier>pmid:37940234</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.820</dc:identifier>
</item>
<item>
<title>Imaging Methods for Evaluation of Chronic Aortic Regurgitation in Adults: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37940233/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109031038&amp;v=2.17.9.post6+86293ac
      <description>A global multidisciplinary workshop was convened to discuss the multimodality diagnostic evaluation of aortic regurgitation (AR). Specifically, the focus was on assessment tools for AR severity and analyzing evolving data on the optimal timing of aortic valve intervention. The key concepts from this expert panel are summarized as: 1) echocardiography is the primary imaging modality for assessment of AR severity; however, when data is incongruent or incomplete, cardiac magnetic resonance may be...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 14;82(20):1953-1966. doi: 10.1016/j.jacc.2023.08.051.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">A global multidisciplinary workshop was convened to discuss the multimodality diagnostic evaluation of aortic regurgitation (AR). Specifically, the focus was on assessment tools for AR severity and analyzing evolving data on the optimal timing of aortic valve intervention. The key concepts from this expert panel are summarized as: 1) echocardiography is the primary imaging modality for assessment of AR severity; however, when data is incongruent or incomplete, cardiac magnetic resonance may be helpful; 2) assessment of left ventricular size and function is crucial in determining the timing of intervention; 3) recent evidence suggests current cutpoints for intervention in asymptomatic severe AR patients requires further scrutiny; 4) left ventricular end-systolic volume index has emerged as an additional parameter that has promise in guiding timing of intervention; and 5) the role of additional factors (including global longitudinal strain, regurgitant fraction, and myocardial extracellular volume) is worthy of future investigation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37940233/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109031038&v=2.17.9.post6+86293ac">37940233</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.051>10.1016/j.jacc.2023.08.051</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37940233</guid>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Lauren S Ranard</dc:creator>
<dc:creator>Robert O Bonow</dc:creator>
<dc:creator>Rick Nishimura</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:creator>Vinod H Thourani</dc:creator>
<dc:creator>Joseph Bavaria</dc:creator>
<dc:creator>Patrick T O'Gara</dc:creator>
<dc:creator>Jeroen J Bax</dc:creator>
<dc:creator>Philipp Blanke</dc:creator>
<dc:creator>Victoria Delgado</dc:creator>
<dc:creator>Jonathon Leipsic</dc:creator>
<dc:creator>Roberto M Lang</dc:creator>
<dc:creator>Hector I Michelena</dc:creator>
<dc:creator>João L Cavalcante</dc:creator>
<dc:creator>Torsten P Vahl</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Vera H Rigolin</dc:creator>
<dc:creator>Heart Valve Collaboratory</dc:creator>
<dc:date>2023-11-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Imaging Methods for Evaluation of Chronic Aortic Regurgitation in Adults: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:37940233</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.051</dc:identifier>
</item>
<item>
<title>A New Hope for Deep Learning-Based Echocardiogram Interpretation: The DROIDs You Were Looking For</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37940232/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109031038&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 14;82(20):1949-1952. doi: 10.1016/j.jacc.2023.09.799.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37940232/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109031038&v=2.17.9.post6+86293ac">37940232</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.799>10.1016/j.jacc.2023.09.799</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37940232</guid>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Márton Tokodi</dc:creator>
<dc:creator>Attila Kovács</dc:creator>
<dc:date>2023-11-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>A New Hope for Deep Learning-Based Echocardiogram Interpretation: The DROIDs You Were Looking For</dc:title>
<dc:identifier>pmid:37940232</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.799</dc:identifier>
</item>
<item>
<title>Deep Learning-Enabled Assessment of Left Heart Structure and Function Predicts Cardiovascular Outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37940231/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109031038&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Deep learning echocardiographic interpretation accurately quantified standard measures of left heart structure and function, which in turn were associated with future clinical outcomes. Deep learning may enable automated echocardiogram interpretation and disease prediction at scale.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 14;82(20):1936-1948. doi: 10.1016/j.jacc.2023.09.800.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Deep learning interpretation of echocardiographic images may facilitate automated assessment of cardiac structure and function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We developed a deep learning model to interpret echocardiograms and examined the association of deep learning-derived echocardiographic measures with incident outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We trained and validated a 3-dimensional convolutional neural network model for echocardiographic view classification and quantification of left atrial dimension, left ventricular wall thickness, chamber diameter, and ejection fraction. The training sample comprised 64,028 echocardiograms (n = 27,135) from a retrospective multi-institutional ambulatory cardiology electronic health record sample. Validation was performed in a separate longitudinal primary care sample and an external health care system data set. Cox models evaluated the association of model-derived left heart measures with incident outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Deep learning discriminated echocardiographic views (area under the receiver operating curve >;0.97 for parasternal long axis, apical 4-chamber, and apical 2-chamber views vs human expert annotation) and quantified standard left heart measures (R<sup>2</sup> range = 0.53 to 0.91 vs study report values). Model performance was similar in 2 external validation samples. Model-derived left heart measures predicted incident heart failure, atrial fibrillation, myocardial infarction, and death. A 1-SD lower model-left ventricular ejection fraction was associated with 43% greater risk of heart failure (HR: 1.43; 95% CI: 1.23-1.66) and 17% greater risk of death (HR: 1.17; 95% CI: 1.06-1.30). Similar results were observed for other model-derived left heart measures.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Deep learning echocardiographic interpretation accurately quantified standard measures of left heart structure and function, which in turn were associated with future clinical outcomes. Deep learning may enable automated echocardiogram interpretation and disease prediction at scale.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37940231/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109031038&v=2.17.9.post6+86293ac">37940231</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.800>10.1016/j.jacc.2023.09.800</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37940231</guid>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Emily S Lau</dc:creator>
<dc:creator>Paolo Di Achille</dc:creator>
<dc:creator>Kavya Kopparapu</dc:creator>
<dc:creator>Carl T Andrews</dc:creator>
<dc:creator>Pulkit Singh</dc:creator>
<dc:creator>Christopher Reeder</dc:creator>
<dc:creator>Mostafa Al-Alusi</dc:creator>
<dc:creator>Shaan Khurshid</dc:creator>
<dc:creator>Julian S Haimovich</dc:creator>
<dc:creator>Patrick T Ellinor</dc:creator>
<dc:creator>Michael H Picard</dc:creator>
<dc:creator>Puneet Batra</dc:creator>
<dc:creator>Steven A Lubitz</dc:creator>
<dc:creator>Jennifer E Ho</dc:creator>
<dc:date>2023-11-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Deep Learning-Enabled Assessment of Left Heart Structure and Function Predicts Cardiovascular Outcomes</dc:title>
<dc:identifier>pmid:37940231</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.800</dc:identifier>
</item>
<item>
<title>Multiomics Insights to Accelerate Drug Development: Will They Hold Their Promises?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37940230/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109031038&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 14;82(20):1932-1935. doi: 10.1016/j.jacc.2023.09.801.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37940230/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109031038&v=2.17.9.post6+86293ac">37940230</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.801>10.1016/j.jacc.2023.09.801</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37940230</guid>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>W H Wilson Tang</dc:creator>
<dc:creator>Wolfgang Koenig</dc:creator>
<dc:date>2023-11-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Multiomics Insights to Accelerate Drug Development: Will They Hold Their Promises?</dc:title>
<dc:identifier>pmid:37940230</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.801</dc:identifier>
</item>
<item>
<title>Multiomics Analysis Provides Novel Pathways Related to Progression of Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37940229/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109031038&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: A systems biology approach integrating genomic, transcriptomic, and proteomic data identified 4 major pathways related to mortality. These pathways are related to decreased activation of the cardioprotective ERBB2 receptor, which can be modified by neuregulin.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 14;82(20):1921-1931. doi: 10.1016/j.jacc.2023.08.053.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Despite major advances in pharmacological treatment for patients with heart failure, residual mortality remains high. This suggests that important pathways are not yet targeted by current heart failure therapies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We sought integration of genetic, transcriptomic, and proteomic data in a large cohort of patients with heart failure to detect major pathways related to progression of heart failure leading to death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used machine learning methodology based on stacked generalization framework and gradient boosting algorithms, using 54 clinical phenotypes, 403 circulating plasma proteins, 36,046 transcript expression levels in whole blood, and 6 million genomic markers to model all-cause mortality in 2,516 patients with heart failure from the BIOSTAT-CHF (Systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure) study. Results were validated in an independent cohort of 1,738 patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The mean age of the patients was 70 years (Q1-Q3: 61-78 years), 27% were female, median N-terminal pro-B-type natriuretic peptide was 4,275 ng/L (Q1-Q3: 2,360-8,486 ng/L), and 7% had heart failure with preserved ejection fraction. During a median follow-up of 21 months, 657 (26%) of patients died. The 4 major pathways with a significant association to all-cause mortality were: 1) the PI3K/Akt pathway; 2) the MAPK pathway; 3) the Ras signaling pathway; and 4) epidermal growth factor receptor tyrosine kinase inhibitor resistance. Results were validated in an independent cohort of 1,738 patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A systems biology approach integrating genomic, transcriptomic, and proteomic data identified 4 major pathways related to mortality. These pathways are related to decreased activation of the cardioprotective ERBB2 receptor, which can be modified by neuregulin.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37940229/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109031038&v=2.17.9.post6+86293ac">37940229</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.053>10.1016/j.jacc.2023.08.053</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37940229</guid>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Wouter Ouwerkerk</dc:creator>
<dc:creator>Joao P Belo Pereira</dc:creator>
<dc:creator>Troy Maasland</dc:creator>
<dc:creator>Johanna E Emmens</dc:creator>
<dc:creator>Sylwia M Figarska</dc:creator>
<dc:creator>Jasper Tromp</dc:creator>
<dc:creator>Andrea L Koekemoer</dc:creator>
<dc:creator>Christopher P Nelson</dc:creator>
<dc:creator>Mintu Nath</dc:creator>
<dc:creator>Simon P R Romaine</dc:creator>
<dc:creator>John G F Cleland</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Dirk J van Veldhuisen</dc:creator>
<dc:creator>Chim C Lang</dc:creator>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:creator>Gerasimos Filippatos</dc:creator>
<dc:creator>Stefan Anker</dc:creator>
<dc:creator>Marco Metra</dc:creator>
<dc:creator>Kenneth Dickstein</dc:creator>
<dc:creator>Leong L Ng</dc:creator>
<dc:creator>Rudolf A de Boer</dc:creator>
<dc:creator>Natal van Riel</dc:creator>
<dc:creator>Max Nieuwdorp</dc:creator>
<dc:creator>Albert K Groen</dc:creator>
<dc:creator>Erik Stroes</dc:creator>
<dc:creator>Aeilko H Zwinderman</dc:creator>
<dc:creator>Nilesh J Samani</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Evgeni Levin</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:date>2023-11-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Multiomics Analysis Provides Novel Pathways Related to Progression of Heart Failure</dc:title>
<dc:identifier>pmid:37940229</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.053</dc:identifier>
</item>
<item>
<title>Plasma Proteomics to Identify Drug Targets for Ischemic Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37940228/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109031038&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Integrated analyses of proteomic and genetic data in Chinese and European adults provided causal support for FURIN and multiple other proteins as potential novel drug targets for treatment of IHD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 14;82(20):1906-1920. doi: 10.1016/j.jacc.2023.09.804.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Integrated analyses of plasma proteomic and genetic markers in prospective studies can clarify the causal relevance of proteins and discover novel targets for ischemic heart disease (IHD) and other diseases.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to examine associations of proteomics and genetics data with IHD in population studies to discover novel preventive treatments.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We conducted a nested case-cohort study in the China Kadoorie Biobank (CKB) involving 1,971 incident IHD cases and 2,001 subcohort participants who were genotyped and free of prior cardiovascular disease. We measured 1,463 proteins in the stored baseline samples using the OLINK EXPLORE panel. Cox regression yielded adjusted HRs for IHD associated with individual proteins after accounting for multiple testing. Moreover, cis-protein quantitative loci (pQTLs) identified for proteins in genome-wide association studies of CKB and of UK Biobank were used as instrumental variables in separate 2-sample Mendelian randomization (MR) studies involving global CARDIOGRAM+C4D consortium (210,842 IHD cases and 1,378,170 controls).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall 361 proteins were significantly associated at false discovery rate &lt;0.05 with risk of IHD (349 positively, 12 inversely) in CKB, including N-terminal prohormone of brain natriuretic peptide and proprotein convertase subtilisin/kexin type 9. Of these 361 proteins, 212 had cis-pQTLs in CKB, and MR analyses of 198 variants in CARDIOGRAM+C4D identified 13 proteins that showed potentially causal associations with IHD. Independent MR analyses of 307 cis-pQTLs identified in Europeans replicated associations for 4 proteins (FURIN, proteinase-activated receptor-1, Asialoglycoprotein receptor-1, and matrix metalloproteinase-3). Further downstream analyses showed that FURIN, which is highly expressed in endothelial cells, is a potential novel target and matrix metalloproteinase-3 a potential repurposing target for IHD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Integrated analyses of proteomic and genetic data in Chinese and European adults provided causal support for FURIN and multiple other proteins as potential novel drug targets for treatment of IHD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37940228/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109031038&v=2.17.9.post6+86293ac">37940228</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.804>10.1016/j.jacc.2023.09.804</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37940228</guid>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Mohsen Mazidi</dc:creator>
<dc:creator>Neil Wright</dc:creator>
<dc:creator>Pang Yao</dc:creator>
<dc:creator>Christiana Kartsonaki</dc:creator>
<dc:creator>Iona Y Millwood</dc:creator>
<dc:creator>Hannah Fry</dc:creator>
<dc:creator>Saredo Said</dc:creator>
<dc:creator>Alfred Pozarickij</dc:creator>
<dc:creator>Pei Pei</dc:creator>
<dc:creator>Yiping Chen</dc:creator>
<dc:creator>Daniel Avery</dc:creator>
<dc:creator>Huaidong Du</dc:creator>
<dc:creator>Dan Valle Schmidt</dc:creator>
<dc:creator>Ling Yang</dc:creator>
<dc:creator>Jun Lv</dc:creator>
<dc:creator>Canqing Yu</dc:creator>
<dc:creator>Junshi Chen</dc:creator>
<dc:creator>Michael Hill</dc:creator>
<dc:creator>Michael V Holmes</dc:creator>
<dc:creator>Joanna M M Howson</dc:creator>
<dc:creator>Richard Peto</dc:creator>
<dc:creator>Rory Collins</dc:creator>
<dc:creator>Derrick A Bennett</dc:creator>
<dc:creator>Robin G Walters</dc:creator>
<dc:creator>Liming Li</dc:creator>
<dc:creator>Robert Clarke</dc:creator>
<dc:creator>Zhengming Chen</dc:creator>
<dc:creator>China Kadoorie Biobank Collaborative Group</dc:creator>
<dc:date>2023-11-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Plasma Proteomics to Identify Drug Targets for Ischemic Heart Disease</dc:title>
<dc:identifier>pmid:37940228</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.804</dc:identifier>
</item>
<item>
<title>Platelet biology and function: plaque erosion vs. rupture</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37940193/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109031038&amp;v=2.17.9.post6+86293ac
      <description>The leading cause of heart disease in developed countries is coronary atherosclerosis, which is not simply a result of ageing but a chronic inflammatory process that can lead to acute clinical events upon atherosclerotic plaque rupture or erosion and arterial thrombus formation. The composition and location of atherosclerotic plaques determine the phenotype of the lesion and whether it is more likely to rupture or to erode. Although plaque rupture and erosion both initiate platelet activation on...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 6:ehad720. doi: 10.1093/eurheartj/ehad720. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The leading cause of heart disease in developed countries is coronary atherosclerosis, which is not simply a result of ageing but a chronic inflammatory process that can lead to acute clinical events upon atherosclerotic plaque rupture or erosion and arterial thrombus formation. The composition and location of atherosclerotic plaques determine the phenotype of the lesion and whether it is more likely to rupture or to erode. Although plaque rupture and erosion both initiate platelet activation on the exposed vascular surface, the contribution of platelets to thrombus formation differs between the two phenotypes. In this review, plaque phenotype is discussed in relation to thrombus composition, and an overview of important mediators (haemodynamics, matrix components, and soluble factors) in plaque-induced platelet activation is given. As thrombus formation on disrupted plaques does not necessarily result in complete vessel occlusion, plaque healing can occur. Therefore, the latest findings on plaque healing and the potential role of platelets in this process are summarized. Finally, the clinical need for more effective antithrombotic agents is highlighted.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37940193/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109031038&v=2.17.9.post6+86293ac">37940193</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad720>10.1093/eurheartj/ehad720</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37940193</guid>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Constance C F M J Baaten</dc:creator>
<dc:creator>Magdolna Nagy</dc:creator>
<dc:creator>Wolfgang Bergmeier</dc:creator>
<dc:creator>Henri M H Spronk</dc:creator>
<dc:creator>Paola E J van der Meijden</dc:creator>
<dc:date>2023-11-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Platelet biology and function: plaque erosion vs. rupture</dc:title>
<dc:identifier>pmid:37940193</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad720</dc:identifier>
</item>
<item>
<title>Growth of the Neo-Aortic Root and Prognosis of Transposition of the Great Arteries</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37939977/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109031038&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Longitudinal surveillance of the neo-aortic root is warranted long after the ASO.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 31:S0735-1097(23)07874-9. doi: 10.1016/j.jacc.2023.10.023. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Neo-aortic root dilatation can lead to significant late morbidity after the arterial switch operation (ASO) for dextro-transposition of the great arteries (d-TGA).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We sought to examine the growth of the neo-aortic root in d-TGA.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A single-center, retrospective cohort study of patients that underwent the ASO from 07/1981-09/2022 was performed. Morphology was categorized as d-TGA with intact ventricular septum (d-TGA-IVS), d-TGA with ventricular septal defect (d-TGA-VSD), and double-outlet right ventricle-TGA type (DORV-TGA). Echocardiographically-determined diameters and derived z-scores were measured at the annulus, sinus of Valsalva (SoV), and sinotubular junction (STJ) immediately before the ASO and throughout follow-up. Trends in root dimensions over time were assessed using linear mixed-effects models. The association between intrinsic morphology and the composite of moderate-severe aortic regurgitation (AR) and neo-aortic valve or root reintervention was evaluated with uni- and multivariable Cox proportional hazards models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 1359 patients that underwent the ASO, 593 (44%), 666 (49%), and 100 (7%) patients had d-TGA-IVS, d-TGA-VSD, and DORV-TGA, respectively. Each patient underwent a median of 5 (IQR 3-10) echocardiograms over a median follow-up of 8.6 years (range 0.1-39.3 years). At 30 years, DORV-TGA patients demonstrated greater annular (p&lt;0.001), SoV (p=0.039), and STJ (p=0.041) dilatation relative to d-TGA-IVS patients. On multivariable analysis, intrinsic anatomy, older age at ASO, at least mild AR at baseline, and high-risk root dilatation were associated with moderate-severe AR and neo-aortic valve or root reintervention at late follow-up (all p&lt;0.05).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Longitudinal surveillance of the neo-aortic root is warranted long after the ASO.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37939977/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109031038&v=2.17.9.post6+86293ac">37939977</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.023>10.1016/j.jacc.2023.10.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37939977</guid>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Aditya Sengupta</dc:creator>
<dc:creator>Chrystalle Katte Carreon</dc:creator>
<dc:creator>Kimberlee Gauvreau</dc:creator>
<dc:creator>Ji M Lee</dc:creator>
<dc:creator>Stephen P Sanders</dc:creator>
<dc:creator>Steven D Colan</dc:creator>
<dc:creator>Pedro J Del Nido</dc:creator>
<dc:creator>John E Mayer</dc:creator>
<dc:creator>Meena Nathan</dc:creator>
<dc:date>2023-11-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Growth of the Neo-Aortic Root and Prognosis of Transposition of the Great Arteries</dc:title>
<dc:identifier>pmid:37939977</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.023</dc:identifier>
</item>
<item>
<title>The neo-aortic root after arterial switch operation: Defining the new normal</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37939976/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109031038&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 30:S0735-1097(23)07917-2. doi: 10.1016/j.jacc.2023.10.024. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37939976/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109031038&v=2.17.9.post6+86293ac">37939976</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.024>10.1016/j.jacc.2023.10.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37939976</guid>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Michael D Seckeler</dc:creator>
<dc:date>2023-11-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The neo-aortic root after arterial switch operation: Defining the new normal</dc:title>
<dc:identifier>pmid:37939976</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.024</dc:identifier>
</item>
<item>
<title>Amiodarone and pulmonary toxicity in atrial fibrillation: a nationwide Israeli study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37939798/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109031038&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSION: In a contemporary AF population, low-dose amiodarone was associated with a trend towards increased risk of ILD (15%-45%) but a clinically negligible change in absolute risk (maximum of 1.8%), no increased risk of PLC, and a lower risk of all-cause mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 6:ehad726. doi: 10.1093/eurheartj/ehad726. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Amiodarone-related interstitial lung disease (ILD) is the most severe adverse effect of amiodarone treatment. Most data on amiodarone-related ILD are derived from periods when amiodarone was given at higher doses than currently used.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A nationwide population-based study was conducted among patients with incident atrial fibrillation (AF) between 1 December 1999 and 31 December 31 2021. Amiodarone-exposed patients were matched 1:1 with controls unexposed to amiodarone based on age, sex, ethnicity, and AF diagnosis duration. The final patient cohort included only matched pairs where amiodarone therapy was consistent throughout follow-up. Directed acyclic graphs and inverse probability treatment weighting (IPTW) modelling were used. Patients with either prior ILD or primary lung cancer (PLC) were excluded. The primary outcome was the incidence of any ILD. Secondary endpoints were death and PLC.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The final cohort included 6039 amiodarone-exposed patients who were matched with unexposed controls. The median age was 73.3 years, and 51.6% were women. After a mean follow-up of 4.2 years, ILD occurred in 242 (2.0%) patients. After IPTW, amiodarone exposure was not significantly associated with ILD [hazard ratio (HR): 1.45, 95% confidence interval (CI): 0.97, 2.44, P = 0.09]. There was a trivial higher relative risk of ILD among amiodarone-exposed patients between Years 2 and 8 of follow-up [maximal risk ratio (RR): 1.019]. Primary lung cancer occurred in 97 (0.8%) patients. After IPTW, amiodarone was not associated with PLC (HR: 1.18, 95% CI: 0.76, 2.08, P = 0.53). All-cause death occurred in 2185 (18.1%) patients. After IPTW, amiodarone was associated with reduced mortality risk (HR: 0.65, 95% CI: 0.60, 0.72, P &lt; 0.001). The results were consistent across a variety of sensitivity analyses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: In a contemporary AF population, low-dose amiodarone was associated with a trend towards increased risk of ILD (15%-45%) but a clinically negligible change in absolute risk (maximum of 1.8%), no increased risk of PLC, and a lower risk of all-cause mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37939798/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109031038&v=2.17.9.post6+86293ac">37939798</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad726>10.1093/eurheartj/ehad726</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37939798</guid>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Gal Tsaban</dc:creator>
<dc:creator>Daniel Ostrovsky</dc:creator>
<dc:creator>Hilmi Alnsasra</dc:creator>
<dc:creator>Nitzan Burrack</dc:creator>
<dc:creator>Michal Gordon</dc:creator>
<dc:creator>Amit Shira Babayev</dc:creator>
<dc:creator>Yara Omari</dc:creator>
<dc:creator>Louise Kezerle</dc:creator>
<dc:creator>David Shamia</dc:creator>
<dc:creator>Sergey Bereza</dc:creator>
<dc:creator>Yuval Konstantino</dc:creator>
<dc:creator>Moti Haim</dc:creator>
<dc:date>2023-11-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Amiodarone and pulmonary toxicity in atrial fibrillation: a nationwide Israeli study</dc:title>
<dc:identifier>pmid:37939798</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad726</dc:identifier>
</item>
<item>
<title>Post-translational modifications upon mitochondrial dysfunction in heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37939789/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109031038&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 6:ehad710. doi: 10.1093/eurheartj/ehad710. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37939789/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109031038&v=2.17.9.post6+86293ac">37939789</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad710>10.1093/eurheartj/ehad710</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37939789</guid>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Joost P G Sluijter</dc:creator>
<dc:creator>Junjie Xiao</dc:creator>
<dc:date>2023-11-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Post-translational modifications upon mitochondrial dysfunction in heart failure</dc:title>
<dc:identifier>pmid:37939789</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad710</dc:identifier>
</item>
<item>
<title>Long-Term Clinical and Echocardiographic Outcomes Following the Ross Procedure: A Post Hoc Analysis of a Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37938855/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109031038&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: This study found that the Ross procedure provided excellent survival into the third decade postoperatively that was comparable to that in the general population. Long-term freedom from reintervention demonstrated that the Ross procedure may be a durable substitute into late adulthood, showing a delayed but progressive functional decline.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 8. doi: 10.1001/jamacardio.2023.4090. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The Ross procedure as treatment for adults with aortic valve disease (AVD) has been the subject of renewed interest.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the long-term clinical and echocardiographic outcomes following the Ross procedure for the treatment of adults with AVD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of a randomized clinical trial included adult patients (age &lt;69 years) who underwent a Ross procedure for the treatment of AVD, including those with active endocarditis, rheumatic AVD, decreased ejection fraction, and previous cardiac surgery. The trial, conducted from September 1, 1994, to May 31, 2001, compared homograft root replacement with the Ross procedure at a single center. Data after 2010 were collected retrospectively in November and December 2022.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Ross procedure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point was long-term survival among patients who underwent the Ross procedure compared with that in the age-, country of origin- and sex-matched general population. Secondary end points were freedom from any reintervention, autograft reintervention, or homograft reintervention and time-related valve function, autograft diameter, and functional status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This study included 108 adults (92 [85%] male) with a median age of 38 years (range, 19-66 years). Median duration of clinical follow-up was 24.1 years (IQR, 22.6-26.1 years; 2488 patient-years), with 98% follow-up completeness. Of these patients, 9 (8%) had active endocarditis and 45 (42%) underwent reoperations. The main hemodynamic lesion was stenosis in 30 (28%) and regurgitation in 49 (45%). There was 1 perioperative death (0.9%). Twenty-five year survival was 83.0% (95% CI, 75.5%-91.2%), representing a relative survival of 99.1% (95% CI, 91.8%-100%) compared with the general population (83.7%). At 25 years, freedom from any reintervention was 71.1% (95% CI, 61.6%-82.0%); from autograft reintervention, 80.3% (95% CI, 71.9%-89.6%); and from homograft reintervention, 86.3% (95% CI, 79.0%-94.3%). Thirty-day mortality after the first Ross-related reintervention was 0% and after all Ross-related reinterventions was 3.8% (n = 1); 10-year survival after reoperation was 96.2% (95% CI, 89.0%-100%).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This study found that the Ross procedure provided excellent survival into the third decade postoperatively that was comparable to that in the general population. Long-term freedom from reintervention demonstrated that the Ross procedure may be a durable substitute into late adulthood, showing a delayed but progressive functional decline.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN03530985.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37938855/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109031038&v=2.17.9.post6+86293ac">37938855</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4090>10.1001/jamacardio.2023.4090</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37938855</guid>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Maximiliaan L Notenboom</dc:creator>
<dc:creator>Giovanni Melina</dc:creator>
<dc:creator>Kevin M Veen</dc:creator>
<dc:creator>Fabio De Robertis</dc:creator>
<dc:creator>Giuditta Coppola</dc:creator>
<dc:creator>Paolo De Siena</dc:creator>
<dc:creator>Emiliano M Navarra</dc:creator>
<dc:creator>Jullien Gaer</dc:creator>
<dc:creator>Michael E K Ibrahim</dc:creator>
<dc:creator>Ismail El-Hamamsy</dc:creator>
<dc:creator>Johanna J M Takkenberg</dc:creator>
<dc:creator>Magdi H Yacoub</dc:creator>
<dc:date>2023-11-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Long-Term Clinical and Echocardiographic Outcomes Following the Ross Procedure: A Post Hoc Analysis of a Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37938855</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4090</dc:identifier>
</item>
<item>
<title>Mendelian Randomization and Cardiovascular Disease-Enabling Expert Readership</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37938849/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109031038&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 8. doi: 10.1001/jamacardio.2023.4126. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37938849/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109031038&v=2.17.9.post6+86293ac">37938849</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4126>10.1001/jamacardio.2023.4126</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37938849</guid>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:date>2023-11-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Mendelian Randomization and Cardiovascular Disease-Enabling Expert Readership</dc:title>
<dc:identifier>pmid:37938849</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4126</dc:identifier>
</item>
<item>
<title>Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37938837/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109031038&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSION AND RELEVANCE: CHIP was significantly and independently associated with risk of CVD in patients with MM undergoing HCT and may serve as a novel biologically plausible biomarker for CVD in this cohort. Patients with MM and both CHIP and cardiovascular risk factors had an exceptionally high risk of CVD. Additional studies are warranted to determine if cardiovascular preventive measures can reduce CHIP-associated CVD risk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 8. doi: 10.1001/jamacardio.2023.4105. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: There is a paucity of information on the association between clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular disease (CVD) in patients with cancer, including those with multiple myeloma (MM) undergoing hematopoietic cell transplant (HCT), a population at high risk of developing CVD after HCT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To examine the association between CHIP and CVD in patients with MM and to describe modifiers of CVD risk among those with CHIP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study of patients with MM who underwent HCT between 2010 and 2016 at City of Hope Comprehensive Cancer Center in Duarte, California, and had pre-HCT mobilized peripheral blood stem cell (PBSC) products cryopreserved and accessible for CHIP analyses. The study team performed targeted panel DNA sequencing to detect the presence of CHIP (variant allele frequency 2% or more).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point was the 5-year cumulative incidence and risk for developing de novo CVD (heart failure, coronary artery disease, or stroke) after HCT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 1036 consecutive patients with MM (580 male [56%]; median age, 60.0 years) who underwent a first autologous HCT, 201 patients had at least 1 CHIP variant (19.4%) and 35 patients had 2 or more variants (3.4%). The 5-year incidence of CVD was significantly higher in patients with CHIP (21.1% vs 8.4%; P &lt; .001) compared with those without CHIP; the 5-year incidence among those with 2 or more variants was 25.6%. In the multivariable model, CHIP was associated with increased risk of CVD (hazard ratio [HR], 2.72; 95% CI, 1.70-4.39), as well as of individual outcomes of interest, including heart failure (HR, 4.02; 95% CI, 2.32-6.98), coronary artery disease (HR, 2.22; 95% CI, 1.06-4.63), and stroke (HR, 3.02; 95% CI, 1.07-8.52). Patients who had both CHIP and preexisting hypertension or dyslipidemia were at nearly 7-fold and 4-fold increased risk of CVD, respectively (reference: no CHIP, no hypertension, or dyslipidemia).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION AND RELEVANCE: CHIP was significantly and independently associated with risk of CVD in patients with MM undergoing HCT and may serve as a novel biologically plausible biomarker for CVD in this cohort. Patients with MM and both CHIP and cardiovascular risk factors had an exceptionally high risk of CVD. Additional studies are warranted to determine if cardiovascular preventive measures can reduce CHIP-associated CVD risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37938837/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109031038&v=2.17.9.post6+86293ac">37938837</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4105>10.1001/jamacardio.2023.4105</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37938837</guid>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>June-Wha Rhee</dc:creator>
<dc:creator>Raju Pillai</dc:creator>
<dc:creator>Tianhui He</dc:creator>
<dc:creator>Alysia Bosworth</dc:creator>
<dc:creator>Sitong Chen</dc:creator>
<dc:creator>Liezl Atencio</dc:creator>
<dc:creator>Artem Oganesyan</dc:creator>
<dc:creator>Kelly Peng</dc:creator>
<dc:creator>Tati Guzman</dc:creator>
<dc:creator>Kara Lukas</dc:creator>
<dc:creator>Brianna Sigala</dc:creator>
<dc:creator>Aleksi Iukuridze</dc:creator>
<dc:creator>Lanie Lindenfeld</dc:creator>
<dc:creator>Faizi Jamal</dc:creator>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:creator>Scott Goldsmith</dc:creator>
<dc:creator>Amrita Krishnan</dc:creator>
<dc:creator>Michael Rosenzweig</dc:creator>
<dc:creator>F Lennie Wong</dc:creator>
<dc:creator>Stephen J Forman</dc:creator>
<dc:creator>Saro Armenian</dc:creator>
<dc:date>2023-11-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant</dc:title>
<dc:identifier>pmid:37938837</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4105</dc:identifier>
</item>
<item>
<title>The Longest Reported Outcomes of the Ross Procedure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37938834/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109031038&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 8. doi: 10.1001/jamacardio.2023.4100. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37938834/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109031038&v=2.17.9.post6+86293ac">37938834</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4100>10.1001/jamacardio.2023.4100</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37938834</guid>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Tsuyoshi Kaneko</dc:creator>
<dc:creator>Maral Ouzounian</dc:creator>
<dc:date>2023-11-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>The Longest Reported Outcomes of the Ross Procedure</dc:title>
<dc:identifier>pmid:37938834</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4100</dc:identifier>
</item>
<item>
<title>Corrected to Open Access Status</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37938826/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109031038&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 8. doi: 10.1001/jamacardio.2023.4300. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37938826/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109031038&v=2.17.9.post6+86293ac">37938826</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4300>10.1001/jamacardio.2023.4300</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37938826</guid>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<dc:date>2023-11-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Corrected to Open Access Status</dc:title>
<dc:identifier>pmid:37938826</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4300</dc:identifier>
</item>
<item>
<title>Mendelian Randomization as a Tool for Cardiovascular Research: A Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37938820/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231109031038&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: This review provides an overview of MR methodology, including assumptions, strengths, and limitations. Several important applications of MR in cardiovascular disease research are highlighted, including the identification of drug targets, evaluation of potential cardiovascular risk factors, as well as emerging methodology. Overall, while MR alone can never prove a causal relationship beyond reasonable doubt, MR offers a rigorous approach for investigating possible...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 8. doi: 10.1001/jamacardio.2023.4115. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Mendelian randomization (MR) is a statistical approach that has become increasingly popular in the field of cardiovascular disease research. It offers a way to infer potentially causal relationships between risk factors and outcomes using observational data, which is particularly important in cases where randomized clinical trials are not feasible or ethical. With the growing availability of large genetic data sets, MR has become a powerful and accessible tool for studying the risk factors for cardiovascular disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBSERVATIONS: MR uses genetic variation associated with modifiable exposures or risk factors to mitigate biases that affect traditional observational study designs. The approach uses genetic variants that are randomly assigned at conception as proxies for exposure to a risk factor, mimicking a randomized clinical trial. By comparing the outcomes of individuals with different genetic variants, researchers may draw causal inferences about the effects of specific risk factors on cardiovascular disease, provided assumptions are met that address (1) the association between each genetic variant and risk factor and (2) the association of the genetic variants with confounders and (3) that the association between each genetic variant and the outcome only occurs through the risk factor. Like other observational designs, MR has limitations, which include weak instruments that are not strongly associated with the exposure of interest, linkage disequilibrium where genetic instruments influence the outcome via correlated rather than direct effects, overestimated genetic associations, and selection and survival biases. In addition, many genetic databases and MR studies primarily include populations genetically similar to European reference populations; improved diversity of participants in these databases and studies is critically needed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This review provides an overview of MR methodology, including assumptions, strengths, and limitations. Several important applications of MR in cardiovascular disease research are highlighted, including the identification of drug targets, evaluation of potential cardiovascular risk factors, as well as emerging methodology. Overall, while MR alone can never prove a causal relationship beyond reasonable doubt, MR offers a rigorous approach for investigating possible causal relationships in observational data and has the potential to transform our understanding of the etiology and treatment of cardiovascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37938820/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231109031038&v=2.17.9.post6+86293ac">37938820</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4115>10.1001/jamacardio.2023.4115</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37938820</guid>
<pubDate>Wed, 08 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Michael G Levin</dc:creator>
<dc:creator>Stephen Burgess</dc:creator>
<dc:date>2023-11-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Mendelian Randomization as a Tool for Cardiovascular Research: A Review</dc:title>
<dc:identifier>pmid:37938820</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4115</dc:identifier>
</item>





























</channel>
</rss>